Mass balance and pharmacokinetics of oral 14C-FYX-051 in healthy male volunteers

Open-label, single-arm trial of topiroxostat in gout and hyperuricemia, sponsored by Fuji Yakuhin. Primary endpoints: Pharmacokinetics, metabolism, routes and extent of elimination, and metabolite identification of FYX-051 and Exposure to and elimination of metabolites of FYX-051. Started Oct 2010; status: active, not recruiting.